Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
37
INO Quote, Financials, Valuation and Earnings
Last price:
$1.73
Seasonality move
:
8.16%
Day range:
$1.64 - $1.74
52-week range:
$1.30 - $2.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
384.51x
P/B ratio:
3.73x
Volume:
965.1K
Avg. volume:
1.1M
1-year change:
-22.07%
Market cap:
$118.9M
Revenue:
$217.8K
EPS (TTM):
-$2.58
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
INO
Inovio Pharmaceuticals, Inc.
|
$400K | -$0.35 | 282.85% | -32.03% | $7.63 |
|
AGEN
Agenus, Inc.
|
$28.2M | -$0.40 | 329.24% | -36.28% | $12.33 |
|
CRIS
Curis, Inc.
|
$3.2M | -$0.31 | -2.86% | -65.51% | $14.00 |
|
LADX
LadRx Corp.
|
-- | -- | -- | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$1.6M | -$0.03 | 22.78% | -97.49% | $5.50 |
|
WINT
Windtree Therapeutics, Inc.
|
-- | -$39.00 | -- | -94.17% | $4.0000 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
INO
Inovio Pharmaceuticals, Inc.
|
$1.73 | $7.63 | $118.9M | -- | $0.00 | 0% | 384.51x |
|
AGEN
Agenus, Inc.
|
$3.06 | $12.33 | $110.6M | -- | $0.00 | 0% | 0.77x |
|
CRIS
Curis, Inc.
|
$1.11 | $14.00 | $14.4M | -- | $0.00 | 0% | 1.06x |
|
LADX
LadRx Corp.
|
$0.0014 | -- | $700 | 0.84x | $0.00 | 0% | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$0.28 | $5.50 | $37.8M | -- | $0.00 | 0% | 4.41x |
|
WINT
Windtree Therapeutics, Inc.
|
$0.0120 | $4.0000 | $404.5K | 0.00x | $0.00 | 0% | 0.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
INO
Inovio Pharmaceuticals, Inc.
|
435.62% | 1.559 | 7.99% | 0.74x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.019 | 285.06% | 0.03x |
|
CRIS
Curis, Inc.
|
192.35% | 2.868 | 144.76% | 0.62x |
|
LADX
LadRx Corp.
|
-- | 2.863 | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
|
WINT
Windtree Therapeutics, Inc.
|
974.23% | 2.926 | 568.87% | 0.01x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
INO
Inovio Pharmaceuticals, Inc.
|
-$749.7K | -$21.2M | -199.9% | -252.43% | -30140.49% | -$21.6M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
CRIS
Curis, Inc.
|
$3.1M | -$6.9M | -147.67% | -461.34% | -218.01% | -$5.6M |
|
LADX
LadRx Corp.
|
-- | -$719.8K | -- | -- | -- | -$552.8K |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
WINT
Windtree Therapeutics, Inc.
|
-$360K | -$3.8M | -320.18% | -760.4% | -- | -$6.4M |
Inovio Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns INO or AGEN?
Agenus, Inc. has a net margin of -30140.49% compared to Inovio Pharmaceuticals, Inc.'s net margin of -116.82%. Inovio Pharmaceuticals, Inc.'s return on equity of -252.43% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INOInovio Pharmaceuticals, Inc.-- -$0.87 $2.3M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About INO or AGEN?
Inovio Pharmaceuticals, Inc. has a consensus price target of $7.63, signalling upside risk potential of 341.23%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 303.05%. Given that Inovio Pharmaceuticals, Inc. has higher upside potential than Agenus, Inc., analysts believe Inovio Pharmaceuticals, Inc. is more attractive than Agenus, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INOInovio Pharmaceuticals, Inc.2 2 0 AGENAgenus, Inc.2 1 0 -
Is INO or AGEN More Risky?
Inovio Pharmaceuticals, Inc. has a beta of 1.722, which suggesting that the stock is 72.239% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.
-
Which is a Better Dividend Stock INO or AGEN?
Inovio Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INO or AGEN?
Inovio Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Inovio Pharmaceuticals, Inc.'s net income of -$45.5M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Inovio Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals, Inc. is 384.51x versus 0.77x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INOInovio Pharmaceuticals, Inc.384.51x -- -- -$45.5M AGENAgenus, Inc.0.77x -- $30.2M $63.9M
-
Which has Higher Returns INO or CRIS?
Curis, Inc. has a net margin of -30140.49% compared to Inovio Pharmaceuticals, Inc.'s net margin of -243.36%. Inovio Pharmaceuticals, Inc.'s return on equity of -252.43% beat Curis, Inc.'s return on equity of -461.34%.
Company Gross Margin Earnings Per Share Invested Capital INOInovio Pharmaceuticals, Inc.-- -$0.87 $2.3M CRISCuris, Inc.98.52% -$0.49 $15.9M -
What do Analysts Say About INO or CRIS?
Inovio Pharmaceuticals, Inc. has a consensus price target of $7.63, signalling upside risk potential of 341.23%. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1161.26%. Given that Curis, Inc. has higher upside potential than Inovio Pharmaceuticals, Inc., analysts believe Curis, Inc. is more attractive than Inovio Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INOInovio Pharmaceuticals, Inc.2 2 0 CRISCuris, Inc.4 0 0 -
Is INO or CRIS More Risky?
Inovio Pharmaceuticals, Inc. has a beta of 1.722, which suggesting that the stock is 72.239% more volatile than S&P 500. In comparison Curis, Inc. has a beta of 3.078, suggesting its more volatile than the S&P 500 by 207.818%.
-
Which is a Better Dividend Stock INO or CRIS?
Inovio Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INO or CRIS?
Inovio Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Curis, Inc. quarterly revenues of $3.2M. Inovio Pharmaceuticals, Inc.'s net income of -$45.5M is lower than Curis, Inc.'s net income of -$7.7M. Notably, Inovio Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals, Inc. is 384.51x versus 1.06x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INOInovio Pharmaceuticals, Inc.384.51x -- -- -$45.5M CRISCuris, Inc.1.06x -- $3.2M -$7.7M
-
Which has Higher Returns INO or LADX?
LadRx Corp. has a net margin of -30140.49% compared to Inovio Pharmaceuticals, Inc.'s net margin of --. Inovio Pharmaceuticals, Inc.'s return on equity of -252.43% beat LadRx Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INOInovio Pharmaceuticals, Inc.-- -$0.87 $2.3M LADXLadRx Corp.-- -$1.45 -- -
What do Analysts Say About INO or LADX?
Inovio Pharmaceuticals, Inc. has a consensus price target of $7.63, signalling upside risk potential of 341.23%. On the other hand LadRx Corp. has an analysts' consensus of -- which suggests that it could grow by 32142757.14%. Given that LadRx Corp. has higher upside potential than Inovio Pharmaceuticals, Inc., analysts believe LadRx Corp. is more attractive than Inovio Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INOInovio Pharmaceuticals, Inc.2 2 0 LADXLadRx Corp.0 0 0 -
Is INO or LADX More Risky?
Inovio Pharmaceuticals, Inc. has a beta of 1.722, which suggesting that the stock is 72.239% more volatile than S&P 500. In comparison LadRx Corp. has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.583%.
-
Which is a Better Dividend Stock INO or LADX?
Inovio Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LadRx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals, Inc. pays -- of its earnings as a dividend. LadRx Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INO or LADX?
Inovio Pharmaceuticals, Inc. quarterly revenues are --, which are larger than LadRx Corp. quarterly revenues of --. Inovio Pharmaceuticals, Inc.'s net income of -$45.5M is lower than LadRx Corp.'s net income of -$719.3K. Notably, Inovio Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while LadRx Corp.'s PE ratio is 0.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals, Inc. is 384.51x versus -- for LadRx Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INOInovio Pharmaceuticals, Inc.384.51x -- -- -$45.5M LADXLadRx Corp.-- 0.84x -- -$719.3K
-
Which has Higher Returns INO or PSTV?
Plus Therapeutics, Inc. has a net margin of -30140.49% compared to Inovio Pharmaceuticals, Inc.'s net margin of -316.61%. Inovio Pharmaceuticals, Inc.'s return on equity of -252.43% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INOInovio Pharmaceuticals, Inc.-- -$0.87 $2.3M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About INO or PSTV?
Inovio Pharmaceuticals, Inc. has a consensus price target of $7.63, signalling upside risk potential of 341.23%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1900%. Given that Plus Therapeutics, Inc. has higher upside potential than Inovio Pharmaceuticals, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Inovio Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INOInovio Pharmaceuticals, Inc.2 2 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is INO or PSTV More Risky?
Inovio Pharmaceuticals, Inc. has a beta of 1.722, which suggesting that the stock is 72.239% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock INO or PSTV?
Inovio Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INO or PSTV?
Inovio Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Inovio Pharmaceuticals, Inc.'s net income of -$45.5M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Inovio Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals, Inc. is 384.51x versus 4.41x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INOInovio Pharmaceuticals, Inc.384.51x -- -- -$45.5M PSTVPlus Therapeutics, Inc.4.41x -- $1.4M -$4.4M
-
Which has Higher Returns INO or WINT?
Windtree Therapeutics, Inc. has a net margin of -30140.49% compared to Inovio Pharmaceuticals, Inc.'s net margin of --. Inovio Pharmaceuticals, Inc.'s return on equity of -252.43% beat Windtree Therapeutics, Inc.'s return on equity of -760.4%.
Company Gross Margin Earnings Per Share Invested Capital INOInovio Pharmaceuticals, Inc.-- -$0.87 $2.3M WINTWindtree Therapeutics, Inc.-- -$1.08 $1.3M -
What do Analysts Say About INO or WINT?
Inovio Pharmaceuticals, Inc. has a consensus price target of $7.63, signalling upside risk potential of 341.23%. On the other hand Windtree Therapeutics, Inc. has an analysts' consensus of $4.0000 which suggests that it could grow by 33233.33%. Given that Windtree Therapeutics, Inc. has higher upside potential than Inovio Pharmaceuticals, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than Inovio Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INOInovio Pharmaceuticals, Inc.2 2 0 WINTWindtree Therapeutics, Inc.0 0 0 -
Is INO or WINT More Risky?
Inovio Pharmaceuticals, Inc. has a beta of 1.722, which suggesting that the stock is 72.239% more volatile than S&P 500. In comparison Windtree Therapeutics, Inc. has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.733%.
-
Which is a Better Dividend Stock INO or WINT?
Inovio Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Windtree Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Windtree Therapeutics, Inc. pays out 36.77% of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios INO or WINT?
Inovio Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Windtree Therapeutics, Inc. quarterly revenues of --. Inovio Pharmaceuticals, Inc.'s net income of -$45.5M is lower than Windtree Therapeutics, Inc.'s net income of -$28.1M. Notably, Inovio Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Windtree Therapeutics, Inc.'s PE ratio is 0.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals, Inc. is 384.51x versus 0.26x for Windtree Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INOInovio Pharmaceuticals, Inc.384.51x -- -- -$45.5M WINTWindtree Therapeutics, Inc.0.26x 0.00x -- -$28.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
